ChromaCode
PrivateLast Round
Series A
Extension
Jan 30, 2025
Total Funding Raised
$66.55M
Company Overview
ChromaCode operates in Healthcare & Life Sciences and is based in Carlsbad, California. Its latest recorded funding round was a Series A Extension round in January 2025.
ChromaCode is a molecular diagnostics company that develops a genomics multiplexing platform utilizing High-Definition PCR technology to enable rapid, accurate, and cost-effective molecular diagnostics testing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware + Subscription, Usage-Based SaaS
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ChromaCode Comparables
Compare ChromaCode with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aplex Bio | 74% | |
| Signal Bioscience | 71% | |
| Thermo Fisher Scientific Inc. | 71% |
For institutional investors. Book with your work email.
ChromaCode Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 30, 2025 | ||||
| Strategic | Jun 7, 2023 | ||||
| Grant | Mar 16, 2021 | ||||
| Series C Extension | May 19, 2020 | ||||
| Series C | Dec 17, 2019 | ||||
Series B | Apr 27, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ChromaCode Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Okapi Venture Capital | Series B, Series C Extension, Series A, Series C |
| New Enterprise Associates | Series C Extension, Series C, Series B |
| Domain Associates | Series B, Series C Extension, Series C, Series A |
| Moore Venture Partners | Series C Extension, Series C |
| Global Brain Corporation | Strategic |
| California Institute of Technology Investment Office | Series C Extension, Series C |
| Northpond Ventures | Series C Extension, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 16, 2021
$500K grant received from XPRIZE Foundation.
- Dec 17, 2019
$38M round led by Adjuvant Capital and Northpond Ventures.
For institutional investors. Book with your work email.
ChromaCode Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ChromaCode's valuation, stock price, and market status.
Is ChromaCode a public or private company?
ChromaCode is a private company.
What is the current stock price of ChromaCode?
ChromaCode is a private company, so its shares have no public market price. Caplight tracks ChromaCode's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ChromaCode worth (valuation)?
Valuation information for ChromaCode is not publicly available.
Can I buy ChromaCode stock?
ChromaCode shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ChromaCode's last funding round?
ChromaCode's most recent funding round was Series A Extension on January 30, 2025.
Who are the main investors in ChromaCode?
Key investors in ChromaCode include New Enterprise Associates, Domain Associates, Global Brain Corporation, Northpond Ventures, Northpond Ventures.
Will ChromaCode IPO soon?
No public IPO plans have been announced for ChromaCode.
How can I track ChromaCode secondary market activity?
Caplight tracks bids, offers, and trades in ChromaCode's shares on secondary markets.